Welcome to today's Medical News Today News Alert containing today's medical news headlines for your chosen categories. You will only receive these alerts when new news is available for your chosen categories.
To unsubscribe from our news alerts, or to alter any of your subscription details (name,e-mail address etc) please see
http://www.medicalnewstoday.com/newsalerts.php?changemydetails=y .
----------------------------------------------
** BREAST CANCER News **
Randomized Phase 2 Study Of IMC-A12 For Advanced Breast Cancer Commences Patient Enrollment
http://www.medicalnewstoday.com/articles/123247.php
ImClone Systems Incorporated (NASDAQ: IMCL), a global leader in the development and commercialization of novel antibodies to treat cancer, today announced that its disease-directed randomized Phase 2 clinical trial of IMC-A12, ImClone's fully human, IgG1 anti-insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody, in women with advanced breast cancer has commenced patient enrollment.
Deactivating A Cancer Growth Promoter
http://www.medicalnewstoday.com/articles/123191.php
Three enzymes called phosphatases that shut down a molecule called SRC-3 (steroid receptor coactivator 3) could provide a new pathway for fighting cancer, particularly tumors of the breast and prostate, said researchers at Baylor College of Medicine in a report that appears in the current issue of the journal</> Molecular Cell.
Concert Pharmaceuticals Presents Preclinical Results Supporting Co-Administration Of CTP-347 And Tamoxifen
http://www.medicalnewstoday.com/articles/123158.php
Concert Pharmaceuticals, Inc. announced today the presentation of data from a preclinical study demonstrating the potential of CTP-347, its novel deuterium-containing serotonin modulator, to avoid the risk of adverse drug-drug interactions when co-administered with tamoxifen, a widely-used breast cancer drug.
Breast, Ovarian Cancer Prediction Models More Accurate For White Women Than Asian-American Women, Study Finds
http://www.medicalnewstoday.com/articles/123145.php
Two widely used prediction models for identifying a woman's risk for breast and ovarian cancer appear to be less reliable for Asian-American women compared with white women, according to a study in the October issue of the <cite>Journal of Clinical Oncology</cite>, <a href="http://www.
----------------------------------------------
** CANCER / ONCOLOGY News **
Cell Phone Use And Tumors: Congress Hears What Science Has To Say
http://www.medicalnewstoday.com/articles/123266.php
A US House of Congress Subcommittee on Domestic Policy heard what science has to say about cell phone use and brain tumors on Thursday. Witnesses included representatives from the Federal Communications Commission, two cancer institutes, university research centres, and Mrs Ellie Marks of Lafayette, California, whose husband discovered he had a tumor on the right side of his brain in May this year.
High Levels Of Compliance And Patient/Physician Satisfaction Reported As CAPHOSOL(R) Unveils Positive Final Data
http://www.medicalnewstoday.com/articles/123249.php
New data show that CAPHOSOL® (<a href="http://www.caphosol.com/" target="_blank" rel="nofollow">http://www.caphosol.com/</a>), an advanced electrolyte solution, significantly limits the occurrence and severity of oral mucositis (OM) in cancer patients undergoing chemotherapy and radiation therapy.
Randomized Phase 2 Study Of IMC-A12 For Advanced Breast Cancer Commences Patient Enrollment
http://www.medicalnewstoday.com/articles/123247.php
ImClone Systems Incorporated (NASDAQ: IMCL), a global leader in the development and commercialization of novel antibodies to treat cancer, today announced that its disease-directed randomized Phase 2 clinical trial of IMC-A12, ImClone's fully human, IgG1 anti-insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody, in women with advanced breast cancer has commenced patient enrollment.
NVP-LBH589 And NVP-LAQ824 - 2 Novel Histone Deacetylase Inhibitors Against Human Pancreatic Cancer
http://www.medicalnewstoday.com/articles/123220.php
Pancreatic cancer is the fifth to sixth leading cause of cancer death in Europe and the fourth leading cause of cancer death in the USA. The lethality of this malignancy is demonstrated by the fact that the annual incidence is approximately equal to the annual deaths.
Identification Of Novel Inhibitor Of Human MicroRNA
http://www.medicalnewstoday.com/articles/123202.php
Scientists at The Wistar Institute and their colleagues have identified, for the first time, a molecule that can regulate microRNAs - short strands of RNA that play a vital role in gene expression and are closely associated with cancer.
Novartis' Once Daily Iron Chelator, Exjade(R) (deferasirox) Awarded Prestigious UK Prix Galien Medicines Prize
http://www.medicalnewstoday.com/articles/123200.php
Exjade (deferasirox) has been awarded a prestigious Prix Galien award for innovative research and development in orphan drugs. The once-daily oral iron chelator from Novartis treats patients with transfusion iron overload.
Value Of Screening In Bladder Cancer
http://www.medicalnewstoday.com/articles/123197.php
BERLIN, GERMANY (UroToday.com) - Dr. Kurt Miller, Professor of Urology at Univsitätsmedizin, Berlin, reviewed the status of screening for bladder cancer. Dr. Miller indicated that for screening to be appropriate, the disease needs to pose a significant health problem to the patient, there has to be an asymptomatic "preclinical" stage during which the disease would be detectable, effective treatments need to be available, and it must be shown that early treatment improves prognosis and survival.
A Promising Approach In The Prevention And Treatment Of Pancreatic Cancer
http://www.medicalnewstoday.com/articles/123169.php
Many gastrointestinal tumors, including pancreatic cancer, have been shown to overexpress the EGFR. The overexpression of EGFR correlates with rapidly progressive disease and poor prognosis. Targeting EGFR pathway as a potential therapeutic strategy for pancreatic cancer has been developed.
Selection Of Patients For ReTURBT In Patients Presenting With Presumed Non-Muscle Invasive Bladder Cancer
http://www.medicalnewstoday.com/articles/123164.php
BERLIN, GERMANY (UroToday.com) - S. Machele Donat, MD, Associate Attending Surgeon, Memorial Sloan-Kettering Cancer Center, presented the MSKCC experience with reTURBT in patients presenting with presumed non-muscle invasive bladder cancer.
Lymphadenectomy In Conjunction With Radical Cystectomy
http://www.medicalnewstoday.com/articles/123161.php
BERLIN, GERMANY (UroToday.com) - Harry W. Herr, MD and Attending Surgeon, Memorial Sloan-Kettering Cancer Center in New York, discussed the value of lymph node dissection in conjunction with radical cystectomy in the treatment of muscle invasive bladder cancer.
Fluorescent Cystoscopy And Photodynamic Diagnosis
http://www.medicalnewstoday.com/articles/123159.php
BERLIN, GERMANY (UroToday.com) - Dr. Christian Stief, Department of Urology, Ludwig-Maximilians-Universität, Munich, presented an update on the biologic and clinical significance of photodynamic diagnosis (PDD) using blue light cystoscopy in the diagnosis of transitional cell cancer of the bladder.
Accuray Incorporated And IMPAC Medical Systems To Link CyberKnife(R) Robotic Radiosurgery System With MOSAIQ(R) EMR
http://www.medicalnewstoday.com/articles/123154.php
Accuray Incorporated (Nasdaq: ARAY) and IMPAC Medical Systems, Inc. announced today that they will collaborate to develop inter-operability between the CyberKnife® Robotic Radiosurgery System and the MOSAIQ® oncology information system.
Accuray Launches New Configuration For CyberKnife System To Offer Hospitals Installation Flexibility
http://www.medicalnewstoday.com/articles/123153.php
Accuray Incorporated (Nasdaq: ARAY), a global leader in the field of radiosurgery, announced today that it is offering a new layout for the CyberKnife® Robotic Radiosurgery System treatment vault which will enable installation of the System into most existing conventional gantry LINAC vaults.
Gap In Black, White New Cancer Diagnoses Narrowing In Missouri; Mortality Rate Gap Falling More Slowly, Study Finds
http://www.medicalnewstoday.com/articles/123146.php
The gap between blacks and whites in Missouri for newly diagnosed cancers is narrowing in part because of an overall decline in smoking and an increase in cancer screenings, according to a study to be published early next year in the journal <cite>Missouri Medicine</cite>, the <a href="http://hosted.
Higher Than Normal Levels Of Two Proteins In Cancer Cells Could Lead Researchers To A Target For Many Types Of Cancer
http://www.medicalnewstoday.com/articles/123110.php
Van Andel Institute (VAI) researchers have identified a possible cancer drug target that could be common to many types of cancer. Higher than normal levels of the proteins Cdc7 and Dbf4 in many types of tumors suggest that the Cdc7-Dbf4 protein kinase, an enzyme crucial to cell division, may be a useful therapeutic target.
$393m Spike In Cancer Hospital Bill Shows Reform Needed Now, Australia
http://www.medicalnewstoday.com/articles/123102.php
Cancer has moved from ninth to fifth on the list of most costly diseases to Australia's health system in only four years, strengthening the case for more investment in cancer prevention and health workforce, Cancer Council Australia said today (26/9).
Melanoma Research Included In 2009 Defense Appropriations, USA
http://www.medicalnewstoday.com/articles/123098.php
The Department of Defense is seeking $4 million dedicated to research efforts on melanoma and other skin cancers, a danger facing many military personnel. As part of the Fiscal 2009 Department of Defense Appropriations Conference Report, the House of Representatives is currently considering the measure.
Attacking Cancer Cells With A Zone Of Resistance
http://www.medicalnewstoday.com/articles/123089.php
A new study published in the journal <i>Molecular Therapy</i>reports on a new way to fight brain tumors using genetic therapy.Researchers from the Massachusetts General Hospital (MGH) were able tointroduce a cancer-fighting gene into normal mouse brain tissue near atumor that prevented the tumor from spreading.
Tyverb® Demonstrates Encouraging Results In Phase II Study In Advanced Head And Neck Cancer
http://www.medicalnewstoday.com/articles/123085.php
GlaxoSmithKline's (GSK) oral targeted agent Tyverb® (lapatinib) demonstrated single agent activity and improvement in clinical response to the subsequent standard chemoradiation compared to placebo in a Phase II study of advanced squamous cell carcinoma of the head and neck (SCCHN).
Eating Walnuts Slows Cancer Growth, Laboratory Study Finds
http://www.medicalnewstoday.com/articles/123073.php
Snack-sized quantities of walnuts slow cancer growth in mice, reports a Marshall University pilot study published in the current issue of the peer-reviewed journal Nutrition and Cancer. Researcher W.
----------------------------------------------
** CERVICAL CANCER / HPV VACCINE News **
Guided Therapeutics, Inc. Announces Completion Of Subject Enrollment Of FDA Pivotal Clinical Trial
http://www.medicalnewstoday.com/articles/123241.php
Guided Therapeutics, Inc. (GT) (Pink Sheets: GTHP) today announced completion of its U.S. Food and Drug Administration (FDA) pivotal clinical trial for its <a href="http://www.guidedtherapeutics.
----------------------------------------------
** COLORECTAL CANCER News **
Global Insight's Analysis Of Nice's Rejection Of Cancer Drug Erbitux For NHS Use, UK
http://www.medicalnewstoday.com/articles/123198.php
Global Insight's Senior Analyst/Oncology Gustav Ando's note on NICE's rejection of cancer drug Erbitux for NHS use. "In another setback for patients in the U.K., an important new colorectal cancer treatment called Erbitux has been deemed too expensive to become readily available on the NHS.
DiagnoCure's GCC Marker For The Staging Of Colorectal Cancer Discussed At Two Scientific Meetings
http://www.medicalnewstoday.com/articles/123079.php
DiagnoCure Inc. (TSX: CUR), a life sciences company commercializing high-value cancer diagnostic tests and delivering laboratory services, announced that its Guanylyl Cyclase C (GCC) marker for identifying colorectal cancer cells is being featured at two scientific meetings this month.
----------------------------------------------
** LUNG CANCER News **
Radiation, Immunotherapy Gives Greater Effectiveness, Says OHSU Cancer Institute Researcher
http://www.medicalnewstoday.com/articles/123181.php
Oregon Health & Science University Cancer Institute researchers have found the right formula of radiation and immunotherapy for fighting lung cancer tumors in mice, which they hope will translate to better treatment in human lung cancers.
Missed Opportunities For Empathy In Interactions With Lung Cancer Patients
http://www.medicalnewstoday.com/articles/123090.php
Physicians seldom responded empathetically to the concerns of patientswith lung cancer in a small study released on September 22, 2008 in <i>Archivesof Internal Medicine</i>, one of the JAMA/Archives journals.
----------------------------------------------
** LYMPHOMA / LEUKEMIA News **
No news for this category today.
----------------------------------------------
** PROSTATE / PROSTATE CANCER News **
Gene Panel Model Predictive Of Male Outcome At High Systemic Progression And Death Risk From Prostate Cancer After Radical Retropubic Prostatectomy
http://www.medicalnewstoday.com/articles/123211.php
UroToday.com - In the August 20, 2008 issue of the <i>Journal of Clinical Oncology</i>, Dr. John C. Cheville and associates from the Mayo Clinic proposed a predictive model, that includes genetic markers, for men at high risk of prostate cancer progression after radical prostatectomy (RP).
Prostate Screening In Patients With 46,XY Disorders Of Sex Development - Is It Necessary?
http://www.medicalnewstoday.com/articles/123208.php
UroToday.com - Whether intersex patients should undergo prostate cancer (CaP) screening is unclear. In the October issue of the <i>Journal of Urology</i>, Dr. Amirali Hassanzadeh Salmasi and colleagues at Johns Hopkins evaluated such a patient population and provided recommendations.
Dutasteride In The Treatment Of Hormone Refractory Prostate Cancer
http://www.medicalnewstoday.com/articles/123206.php
UroToday.com - Incidence of prostate cancer is on the rise. Approximately 10 to 20 percent of men with prostate cancer present with metastatic disease, and in many others metastases develop despite treatment with surgery or radiotherapy.
Deactivating A Cancer Growth Promoter
http://www.medicalnewstoday.com/articles/123191.php
Three enzymes called phosphatases that shut down a molecule called SRC-3 (steroid receptor coactivator 3) could provide a new pathway for fighting cancer, particularly tumors of the breast and prostate, said researchers at Baylor College of Medicine in a report that appears in the current issue of the journal</> Molecular Cell.
InTempo™ Adaptive Imaging System To Addresses Prostate Motion That Commonly Occurs During Radiation Treatment Delivery
http://www.medicalnewstoday.com/articles/123152.php
Accuray Incorporated (Nasdaq: ARAY), a global leader in the field of radiosurgery, introduced the InTempo™ Adaptive Imaging System, which enhances the CyberKnife® Robotic Radiosurgery System's ability to continually track and correct for motion of the prostate during treatment.
Debiopharm Moves Towards A New 6-Month Formulation Of Decapeptyl(R) To Further Help Prostate Cancer Patients
http://www.medicalnewstoday.com/articles/123070.php
Debiopharm Group (Debiopharm), a global biopharmaceutical development specialist that focuses on serious medical conditions and particularly oncology, announces the filing of an application with the European Agencies for the approval of its new 6-month formulation of Decapeptyl(R) (triptorelin pamoate 22.
-------------------------------------------------------------
You are receiving this news alert e-mail because you subscribed via an online form on our web site. If you wish to unsubscribe, please visit
http://www.medicalnewstoday.com/newsalerts.php?changemydetails=y .
No comments:
Post a Comment